Case Report: Exenatide Use During Pregnancy
The DOI matches its Crossref record, with a small difference in title or year; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Objective: To describe the effects on pregnancy outcomes of exposure to exenatide through the first trimester of pregnancy. Methods: A 35-year-old woman with type 2 diabetes mellitus, hypertension, infertility, oligomenorrhea, and morbid obesity, conceived spontaneously while taking multiple medications, including exenatide. The pregnancy was diagnosed incidentally at 14 weeks gestational age, and exenatide was discontinued at that time. Results: Fetal ultrasonography and echocardiography revealed no anomalies, and fetal growth was normal. Preeclampsia became superimposed on chronic hypertension at 38 weeks, and a complicated labor and delivery followed. No congenital anomalies were observed in the infant. Conclusions: In this one case, there were no congenital malformations or other adverse outcomes of pregnancy after exposure to exenatide through the first trimester. This case underscores the importance of counseling all women of reproductive age with preexisting diabetes regarding pregnancy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this case, after an uneventful pregnancy, the patient delivered an anatomically normal fetus despite exposure to exenatide during the period of organogenesis.”
From Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence (2023) · cites this paper as [33]
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Maternal Morbid Obesity and the Risk of Adverse Pregnancy Outcome
Cedergren, M. I. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000107291.46159.00 · Cited by 1,248
Major congenital malformations after first-trimester exposure to ACE inhibitors
Cooper, W. O., Hernandez-Diaz, S., Arbogast, P. G., Dudley, J. A., Dyer, S., Gideon, P. S., Hall, K., & Ray, W. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055202 · Cited by 1,192
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279
Hoeger, K. M., Kochman, L., Wixom, N., Craig, K., Miller, R. K., & Guzick, D. S. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.02.104 · Cited by 278
Huber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
The impact of bariatric surgery on menstrual patterns
Teitelman, M., Grotegut, C., Williams, N., & Lewis, J. (2006) · Obesity Surgery · doi:10.1381/096089206778870148 · Cited by 179
Movassat, J., Beattie, G. M., Lopez, A. D., & Hayek, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020137 · Cited by 104
The Development of Beta-cell Mass: Recent Progress and Potential Role of GLP-1
Stoffers, D. A. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826168 · Cited by 92
Incretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
Teratology public affairs committee position paper: Maternal obesity and pregnancy
Scialli, A. R. (2006) · Birth Defects Research Part A: Clinical and Molecular Teratology · doi:10.1002/bdra.20236 · Cited by 57
Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)
Hiles, R. A., Bawdon, R. E., & Petrella, E. M. (2003) · Human & Experimental Toxicology · doi:10.1191/0960327103ht402oa · Cited by 46
Segal, J. B., Dy, S. M., Millman, E. A., Herbert, R. J., Bass, E. B., & Wu, A. W. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.021 · Cited by 21
Research works printed but not linked: 1
- Huber-Buchholz, 1999, J Clin Endocrinol Metab, 84, 1470
Cited by
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215356 · Cited by 174
Garcia-Flores, V., Romero, R., Miller, D., Xu, Y., Done, B., Veerapaneni, C., Leng, Y., Arenas-Hernandez, M., Khan, N., Panaitescu, B., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01291 · Cited by 71
Zhou, L., Qu, H., Yang, L., & Shou, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01500-5 · Cited by 66
Metadata
- Authors
- Williams, J., Pomeroy, N. E., Pop-Busui, R., Lash, R., Douyon, L., Chames, M., & Wyckoff, J.
- Affiliations
- University of Michigan (US)
- Corresponding author
- Williams, Jennifer
- Chames, Mark
- Venue
- The Endocrinologist
- Published
- 2009-05
- Volume
- 19
- Issue
- 3
- Pages
- 119-121
- ISSN
- 1051-2144 (ISSN-L)
- OpenAlex
- W1966284758
- Cited by
- 21
- References
- 17
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 3 · 2023: 2 · 2018: 1 · 2014: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Endocrinologist (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- exenatide, type 2 diabetes, pregnancy, first trimester drug exposure, congenital malformations, fetal growth, preeclampsia, maternal obesity, infertility, reproductive counseling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.